Latest Breaking News On - மறுக்க ஶூ - Page 1 : vimarsana.com

 E-Mail SILVER SPRING, Md. - A recent preclinical study by U.S. Military HIV Research Program (MHRP) researchers showed that an experimental therapy combining a TLR7 agonist and two broadly neutralizing antibodies delayed viral rebound in SHIV-infected macaques after antiretroviral therapy (ART) interruption. The experimental combination therapy consisted of TLR7 agonist GS-986 and two broadly neutralizing antibodies (bnAbs), N6-LS and PGT121, targeting different regions of the HIV envelope. The rhesus macaques were initiated on viral suppressive antiretroviral therapy 14 days post infection, a timespan from infection to treatment which mirrors what is feasible in acute HIV infection. Researchers then administered the experimental combination therapy, followed by ART pause and measured how long it took for SHIV viral load to rebound.

Krung thep mahanakhonDenise hsuWalter reed army institute of researchResearch programResearch centreWalter reed army instituteThai red crossSandhya vasanMedicine healthAids hivImmunology allergies asthmaInfectious emerging diseasesமறுக்க ஶூவால்டர் நாணல் இராணுவம் நிறுவனம் ஆஃப் ஆராய்ச்சிஆராய்ச்சி ப்ரோக்ர்யாம்ஆராய்ச்சி மையம்